These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19624788)

  • 1. The burden and extent of comorbid conditions in patients with erectile dysfunction.
    Hackett G
    Int J Clin Pract; 2009 Aug; 63(8):1205-13. PubMed ID: 19624788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global experiences with vardenafil in men with erectile dysfunction and underlying conditions.
    Eardley I; Lee JC; Guay AT
    Int J Clin Pract; 2008 Oct; 62(10):1594-603. PubMed ID: 18822030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
    Blonde L
    Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
    Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
    Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
    Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C;
    Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical implications of erectile dysfunction.
    Berookhim BM; Bar-Chama N
    Med Clin North Am; 2011 Jan; 95(1):213-21. PubMed ID: 21095424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between erectile dysfunction and cardiovascular risk in men with Type 2 diabetes in primary care: it is a matter of age.
    Cleveringa FG; Meulenberg MG; Gorter KJ; van den Donk M; Rutten GE
    J Diabetes Complications; 2009; 23(3):153-9. PubMed ID: 18413203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus.
    Ryan JG; Gajraj J
    J Diabetes Complications; 2012; 26(2):141-7. PubMed ID: 22437118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Past, present, and future: a 7-year update of Viagra (sildenafil citrate).
    Jackson G; Gillies H; Osterloh I
    Int J Clin Pract; 2005 Jun; 59(6):680-91. PubMed ID: 15924597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, double-blind, placebo-controlled trial to assess the efficacy of sildenafil citrate in men with unrecognized erectile dysfunction.
    Shabsigh R; Kaufman J; Magee M; Creanga D; Russell D; Budhwani M
    Urology; 2010 Aug; 76(2):373-9. PubMed ID: 20579708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of common medical conditions and drug exposures to erectile dysfunction in adult males.
    Francis ME; Kusek JW; Nyberg LM; Eggers PW
    J Urol; 2007 Aug; 178(2):591-6; discussion 596. PubMed ID: 17570434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
    Sussman DO
    J Am Osteopath Assoc; 2004 Mar; 104(3 Suppl 4):S11-5. PubMed ID: 15083994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart.
    Foresta C; Caretta N; Corona G; Fabbri A; Francavilla S; Jannini E; Maggi M; Bettocchi C; Lenzi A
    Int J Androl; 2009 Jun; 32(3):198-211. PubMed ID: 19076256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction and cardiovascular disease.
    Menezes A; Artham S; Lavie CJ; Milani RV; O'Keefe J
    Postgrad Med; 2011 May; 123(3):7-16. PubMed ID: 21566411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study.
    Safarinejad MR; Kolahi AA; Ghaedi G
    BJU Int; 2009 Aug; 104(3):376-83. PubMed ID: 19389004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance of cardiovascular risk factors for outpatients in different erectile dysfunction severity.
    Chang ST; Chu CM; Hsu JT; Lin PC; Shee JJ
    Int J Impot Res; 2009; 21(2):116-21. PubMed ID: 19177147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.